You need the Flash Player version 8.0.0.0 or higher and a JavaScript enabled browser to view this content

Proactive investorsLogo Proactive Investors UK Website

Search field
Get Adobe Flash Player Download
Flash
Player ►

And
Enable
Javascript

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: ASX
Sector: Pharma & Biotech
Epic: BNO
News: Latest news
Web Site: Bionomics Limited
Other Articles: 28-06-201021-06-201007-06-2010

RSS - Subscribe to the News Today on Proactive UK ▼

Saturday September 04, 06:00Serving up support at Babcock

Support services have been among the worst performing sectors over the past month as revenue fears from the government’s austerity measures weigh heavily on the sector.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive NA ▼

Friday September 03, 11:40 Goldcorp snatches Andean Resources in $3.6bn deal, trumping Eldorado`s earlier bid

Both companies are vying for Andean`s Cerro Negro gold project, which is an advanced-stage, high-grade vein system, comprising 215 square kilometers. It currently has indicated resources of 2.54 million ounces of gold and 23.56 million ounces of silver, while inferred resources total 523,000 ounces of gold and 3.12 million ounces of silver.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Wednesday September 01, 10:25Green Dragon Gas reports significant growth as China’s thirst for energy continues

China's thirst for energy resources has continued with an increased focus on domestic supplies of gas, Green Dragon Gas chairman Randeep Grewal said today. In the company's interim results, [...]

FULL ARTICLE ►
Bionomics Limited

Bionomics Limited

Bionomics (ASX: BNO) is a productive drug discovery and development engine room focused on new treatments for cancer and serious disorders of the central nervous system (CNS). Through application of its proprietary technology platforms, MultiCore®, Angene® and ionX®.

The company has generated multiple drug candidates and targets in the therapeutic areas of Cancer, Anxiety, Multiple Sclerosis and Epilepsy. The company has a strong out-license record in conjunction with its in-house development program which has seen two highly promising drugs enter clinical trials in the past two years.

CLICK HERE FOR FULL ANALYSIS OF BIONOMICS LIMITED
Monday, June 07, 2010

Bionomics presents at American Society of Clinical Oncology conference

company news image

Adelaide-based drug discovery and development company Bionomics (ASX: BNO) has presented data from its first-in-human trial for its anti-cancer compound BNC105 at the annual American Society of Clinical Oncology (ASCO) conference in Chicago, Illinois.

BNC105 is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours.

ASCO is a prestigious forum strongly focused on patient-oriented clinical research. The Phase I dose escalation study was conducted in patients with different solid tumours, including colorectal carcinomas, head and neck cancers, renal cell cancer and mesothelioma.

The data shows that BNC105P (the pro-drug form of BNC105) was well tolerated without any serious adverse side effects below the maximum dose of 18.9 mg/m2. Stable disease was observed in 4 of 16 patients who completed at least two cycles of treatment at doses of 8.4 mg/m2 or higher.

Dr Deborah Rathjen, managing director of Bionomics, said “the publication of the outcomes of the successful Phase I trial strengthens confidence in the ongoing development of BNC105 and underpins the rationale of the Phase II trials that are currently in progress."

"We are very excited by the potential of this drug and anticipate initial Phase II data being available as early as the end of this year for the renal cancer trial and in the first half of calendar year 2011 for mesothelioma.”

BNC105 has the potential to treat all solid tumour types. Bionomics has elected renal cell cancer and
mesothelioma as the first Phase II clinical trial indications for BNC105, these have a fast path to market.

Renal cancer was the market entry indication for Sutent (Pfizer) and similarly mesothelioma for Alimta (Lilly). Both are blockbuster drugs with 2009 sales of US$964 million and US$1.7 billion respectively.

AddThis Feed Button
Register here to be notified of Proactiveinvestors One2One Forums.

Other Bionomics Limited articles


Other Bionomics Limited news

More news ►

Investors interested in Bionomics Limited recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.